Galera Therapeutics, Inc. Common Stock
GRTX
GRTX was delisted on the 3rd of June, 2024.
41 hedge funds and large institutions have $134M invested in Galera Therapeutics, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 21 increasing their positions, 3 reducing their positions, and 2 closing their positions.
600% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 3
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
21% more funds holding
Funds holding: 34 → 41 (+7)
17% less capital invested
Capital invested by funds: $160M → $134M (-$26.8M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$6.64M |
| 2 |
BlackRock
New York
|
+$3.46M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.21M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.12M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$751K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$722K |
| 2 |
Squarepoint
New York
|
-$120K |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$68.3K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$28K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$7.35K |
GRTX Hedge Fund Activity: Q2 2020 in Review
41 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Galera Therapeutics, Inc. Common Stock (GRTX) for Q2 2020, worth a combined $134M — down 17% from $160M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new GRTX positions and 2 closed out — a net gain of 7 holders — while 21 added to existing stakes and 3 trimmed.
The largest buyer was Tekla Capital Management, adding an estimated $6.64M. The largest seller was RA Capital Management, cutting an estimated $722K.
- 41 institutional investors held Galera Therapeutics, Inc. Common Stock (GRTX) as of Q2 2020, up from 34 in Q1 2020.
- Funds reported $134M of Galera Therapeutics, Inc. Common Stock stock for Q2 2020, down 17% quarter-over-quarter.
- 9 funds opened new Galera Therapeutics, Inc. Common Stock positions in Q2 2020 and 2 closed out, a net change of +7 holders.
- The largest Galera Therapeutics, Inc. Common Stock buyer in Q2 2020 was Tekla Capital Management, an estimated $6.64M added.
- The largest Galera Therapeutics, Inc. Common Stock seller in Q2 2020 was RA Capital Management, an estimated $722K sold.
Based on aggregated 13F filings for Q2 2020.